Results overview: Found 10 records in 0.01 seconds.
Articles, 7 records found
Research literature, 3 records found
Articles 7 records found  
10 p, 595.1 KB Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma / Wick, Antje (Heidelberg University Medical Center) ; Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke) ; Suarez, Cristina (Vall d'Hebron Institut d'Oncologia) ; Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Burkholder, Tiana (Eli Lilly and Company) ; Cleverly, Ann Louise (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Wang, Shuaicheng (BioStat Solutions (Estats Units)) ; Lahn, Michael M.. (Eli Lilly and Company) ; Guba, Susan C. (Eli Lilly and Company) ; Capper, D. (Charité - Universitätsmedizin Berlin) ; Rodon Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The online version of this article contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00910-9
Investigational New Drugs, Vol. 38 (march 2020) , p. 1570-1579  
9 p, 297.7 KB New clinical trial designs in the era of precision medicine / Garralda, Elena (Universitat Autònoma de Barcelona) ; Dienstmann, Rodrigo (Universitat Autònoma de Barcelona) ; Piris-Giménez, Alejandro (Universitat Autònoma de Barcelona) ; Braña, Irene (Universitat Autònoma de Barcelona) ; Rodon Ahnert, Jordi (Universitat Autònoma de Barcelona) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Universitat Autònoma de Barcelona ; Vall d'Hebron Institut d'Oncologia
Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those deregulations irrespective of the tumour type. [...]
2019 - 10.1002/1878-0261.12465
Molecular Oncology, Vol. 13 (february 2019) , p. 549-557  
8 p, 2.4 MB Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations / Tamborero, David (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rubio-Perez, Carlota (Institut Hospital del Mar d'Investigacions Mèdiques) ; Deu-Pons, Jordi (Institut Hospital del Mar d'Investigacions Mèdiques) ; Schroeder, Michael P. (Charité - Universitätsmedizin Berlin) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Rovira, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ; Tusquets, Ignasi (Institut Hospital del Mar d'Investigacions Mèdiques) ; Albanell Mestres, Joan (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; De Torres, Carmen (Institut de Recerca Sant Joan de Déu) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Gonzalez-Perez, Abel (Institut Hospital del Mar d'Investigacions Mèdiques) ; Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. [...]
2018 - 10.1186/s13073-018-0531-8
Genome Medicine, Vol. 10 (March 2018) , art. 25  
10 p, 506.2 KB Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights / Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Élez Fernández, María Elena (Hospital Universitari Vall d'Hebron) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ; Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; Alsina Maqueda, Maria (Vall d'Hebron Institut d'Oncologia) ; Saurí Nadal, Tamara (Vall d'Hebron Institut d'Oncologia) ; Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ; Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ; Ruiz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ; Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ; García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ; Landolfi, Stefania (Universitat Autònoma de Barcelona) ; Palmer, Héctor G (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272  
8 p, 500.8 KB Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer / Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ; Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ; Desaiah, Durisala (Eli Lilly and Company (USA)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Miles, Colin (Eli Lilly and Company (United Kingdom)) ; Lahn, Michael M.. (Eli Lilly and Company (USA)) ; Mitchell, Malcolm I (Eli Lilly and Company (USA)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303  
14 p, 4.6 MB A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer / Lazar, Vladimir (Gustave-Roussy Cancer Center (France)) ; Rubin, Eitan (Ben-Gurion University of the Negev (Israel)) ; Depil, Stephane (Leon Berard Cancer Center (France)) ; Pawitan, Yudi (Karolinska Institutet (Estocolm, Suècia)) ; Martini, Jean-François (Pfizer Oncology Research (USA)) ; Gomez-Navarro, Jesus (Takeda Pharmaceuticals International Co.(USA)) ; Yver, Antoine (AstraZeneca Pharmaceuticals LP (USA)) ; Kan, Zhengyin (Pfizer Oncology Research (USA)) ; Dry, Jonathan R. (AstraZeneca Pharmaceuticals LP (USA)) ; Kehren, Jeanne (Sanofi (France)) ; Validire, Pierre (Institut Mutualiste Montsouris (France)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vielh, Philippe (Gustave-Roussy Cancer Center (France)) ; Ducreux, Michel (Gustave-Roussy Cancer Center (France)) ; Galbraith, Susan (AstraZeneca Pharmaceuticals LP (USA)) ; Lehnert, Manfred (Takeda Pharmaceuticals International Co. (USA)) ; Onn, Amir (Chaim Sheba Medical Center (Israel)) ; Berger, Raanan (Chaim Sheba Medical Center (Israel)) ; Pierotti, Marco A. (Fondazione IRCCS Istituto Nazionale dei Tumori (Italy)) ; Porgador, Angel (Ben-Gurion University of the Negev (Israel)) ; Pramesh, C. S. (Tata Memorial Centre (India)) ; Ye, Ding-wei (Fudan University Shanghai Cancer Center (China)) ; Carvalho, Andre L. (Barretos Cancer Hospital. Fundacao Pio XII (Brazil)) ; Batist, Gerald (Jewish General Hospita. Segal Cancer Centre (Canada)) ; Le Chevalier, Thierry (Gustave-Roussy Cancer Center (France)) ; Morice, Philippe (Gustave-Roussy Cancer Center (France)) ; Besse, Benjamin (Gustave-Roussy Cancer Center (France)) ; Vassal, Gilles (Gustave-Roussy Cancer Center (France)) ; Mortlock, Andrew (AstraZeneca Pharmaceuticals LP (USA)) ; Hansson, Johan (Karolinska Institutet (Estocolm, Suècia)) ; Berindan Neagoe, Ioana (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Dann, Robert (General Electric Healthcare (USA)) ; Haspel, Joel (Oracle Corporation (UK)) ; Irimie, Alexandru (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Laderman, Steve (Agilent Technologies (USA)) ; Nechushtan, Hovav (Hadassah Hebrew University Medical Center (Israel)) ; Al Omari, Amal S. (King Hussein Cancer Center (Jordan)) ; Haywood, Trent (Blue Cross Blue Shield Association (USA)) ; Bresson, Catherine (WIN Consortium (France)) ; Soo, Khee Chee (National Cancer Centre (Singapore)) ; Osman, Iman (New York University Langone Medical Center (USA)) ; Mata, Hilario (MD Anderson Cancer Center (USA)) ; Lee, Jack J. (MD Anderson Cancer Center (USA)) ; Jhaveri, Komal (New York University Langone Medical Center (USA)) ; Meurice, Guillaume (Gustave-Roussy Cancer Center (France)) ; Palmer, Gary (Foundation Medicine Inc. (USA)) ; Lacroix, Ludovic (Gustave-Roussy Cancer Center (France)) ; Koscielny, Serge (Gustave-Roussy Cancer Center (France)) ; Eterovic, Karina Agda (MD Anderson Cancer Center (USA)) ; Blay, Jean-Yves (Leon Berard Cancer Center (France)) ; Buller, Richard (Pfizer Oncology Research (USA)) ; Eggermont, Alexander (Gustave-Roussy Cancer Center (France)) ; Schilsky, Richard L. (American Society of Clinical Oncology (USA)) ; Mendelsohn, John (MD Anderson Cancer Center (USA)) ; Soria, Jean-Charles (Gustave-Roussy Cancer Center (France)) ; Rothenberg, Mace (Pfizer Oncology Research (USA)) ; Scoazec, Jean-Yves (Gustave-Roussy Cancer Center (France)) ; Ki Hong, Waun (MD Anderson Cancer Center (USA)) ; Kurzrock, Razelle (Moores Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. [...]
2015 - 10.18632/oncotarget.3741
Oncotarget, Vol. 6, no. 16 (June 2015) , p. 14139-14152  
10 p, 687.1 KB A framework for genomic biomarker actionability and its use in clinical decision making / Vidwans, Smruti J. (CollabRx Inc. (USA)) ; Turski, Michelle L. (CollabRx Inc. (USA)) ; Janku, Filip (University of Texas. MD Anderson Cancer Center (USA)) ; Garrido-Laguna, Ignacio (University of Utah. Huntsman Cancer Institute (USA)) ; Munoz, Javier (Banner MD Anderson Cancer Center (USA)) ; Schwab, Richard (University of California. Moores Cancer Center (USA)) ; Subbiah, Vivek (University of Texas. MD Anderson Cancer Center (USA)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Kurzrock, Razelle (University of California. Moores Cancer Center (USA)) ; Universitat Autònoma de Barcelona
The increasing scope and availability of genetic testing options for patients suffering from cancer has raised questions about how to use results of molecular diagnostics to inform patient care. For some biomarkers (e. [...]
2014 - 10.18632/oncoscience.90
Oncoscience, Vol. 1, Núm. 10 (October 2014) , p. 614-623  

Research literature 3 records found  
194 p, 5.1 MB 1 Tesis Doctoral Selección de dosis en el desarrollo de fármacos para el tratamiento del cáncer en pacientes con insuficiencia renal y hepática / Azaro, Analía ; Rodón Ahnert, Jordi, dir. ; Valle, Marta, dir.
Els pacients amb cancer I insuficiència renal (IR) i/o insuficiencia hepática (IH) constitueixen un dels principals reptes en el tractament de el cáncer a causa que els fàrmacs antineoplàstics són pricipalment metabolizats pel fetge i eliminats pel ronyó i les dosis i esquemes de tractaments dels mateixos es van investigars, majoritàriament, en pacients amb funció renal i hepática normal. [...]
Los pacientes con cáncer e insuficiencia renal (IR) y/o insuficiencia hepática (IH) constituyen uno de los principales retos en el tratamiento del cáncer debido a que los fármacos antineoplásicos son principalmente metabolizados por el hígado y eliminados por el riñón y las dosis y esquemas de tratamientos de los mismos se investigaron, en su mayoría, en pacientes con función renal y hepática normal. [...]
Patients with cancer and renal impairment (RI) and /or hepatic impairment (HI) are one of the main challenges in cancer treatment since anti-cancer agents are mainly metabolized by the liver and eliminated by the kidneys and the doses and regimens for treatments were investigated mostly in patients with normal kidney and liver function. [...]

245 p, 5.5 MB Caracterización del mecanismo de acción de los pan-inhibidores selectivos del receptor del factor de crecimiento fibroblástico e identificación de potenciales biomarcadores predictivos de respuesta mediante la utilización de xenoinjertos derivados de pacientes con alteraciones en esta vía molecular / Hierro, Cinta ; Rodón Ahnert, Jordi, dir. ; Serra Elizalde, Violeta, dir. ; Bosch Albareda, Francesc, dir.
En càncer, la desregulació de la via del FGFR:FGF s'ha associat a un creixement tumoral descontrolat, una angiogènesi aberrant i una major capacitat de metastatització. En aquest context, en l'última dècada s'ha fet un gran esforç per desenvolupar fàrmacs dirigits contra aquesta diana terapèutica. [...]
En cáncer, la desregulación de la vía del FGFR:FGF se ha asociado a un crecimiento tumoral descontrolado, una angiogénesis aberrante y una mayor capacidad de metastatización. En este contexto, en la última década se ha realizado un gran esfuerzo en desarrollar fármacos dirigidos contra esta diana terapéutica. [...]
Among cancers, deregulation of the FGFR:FGF pathway has been widely associated with uncontrolled tumoral growth, aberrant angiogenesis and increased metastatic dissemination rates. In this context, several efforts have been done during the last decade in order to develop targeted agents against this molecular pathway. [...]

200 p, 4.9 MB Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer / Rodón Ahnert, Jordi ; Tabernero, Josep, dir. ; Bosch Gil, Josep Àngel ; Universitat Autònoma de Barcelona. Departament de Medicina
Este trabajo se centra en el papel de los biomarcadores en el desarrollo temprano de fármacos en Oncología, e introduce un concepto nuevo como es la implementación precoz de marcadores predictivos de respuesta en estudios fase I como estrategia para acelerar la toma de decisiones en el desarrollo de un fármaco experimental. [...]
This work focuses on the role of biomarkers in the early development of drugs in oncology, and introduces a new concept such as the early implementation of predictive markers of response in phase I studies as a strategy to accelerate decision-making in the development of an experimental drug. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2015  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.